Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients SAN FRANCISCO, CA / ACCESSWIRE / December 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) and its wholly owned subsidiary Napo Pharmaceuticals today announced the third-party presentation of findings from the investigator-initiated HALT-D trial evaluating crofelemer for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane. These therapies cause CID in up to 80% of breast cancer patients, reaching grade 3, which often requires hospitalization, in 8-12% of patients.

Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)

1847 GOEDEKER INC.

GSX Techedu Inc.

With 2021 coming to an end, which penny stocks are you watching? The post Top Penny Stocks to Add to Your Watchlist As 2021 Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Add to Your Watchlist As 2021 Ends

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by over 8% this week. This is why it happened.

Jaguar Health Stock (JAGX): Why The Price Increased This Week

Content from the discussion will be featured in upcoming "Diarrhea Dialogues: Part 2" SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting a closed satellite event on December 9, 2021 at SABCS in San Antonio, Texas. The evening includes a discussion with leading oncologists on the debilitating effects of diarrhea experienced as a result of cancer and/or cancer therapy.

Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company's Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)

Atai Life Sciences BV

COMPASS Pathways

Cybin

Ameri Holdings

Field Trip Health Ltd

GH Research PLC

Mind Medicine MindMed

Seelos Therapeutics

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.

9 Psychedelic Stocks to Watch For 2022

Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea (CID). The trial included HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab, and a taxane.

Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients

Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2 HALT-D trial evaluating crofelemer for the prevention of chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane.1 These therapies are known to cause CID in up to 80% of breast cancer patients, reaching grade 3 (requiring hospitalization) in 8-12% of patients.2-5 CID can have a negative impact on quality of life, particularly when it persists through much of the course of chemotherapy, and may result in stopping cancer treatment. There are no medications currently approved for CID.

Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2021 Results - Earnings Call Transcript

Jaguar Health (NASDAQ:JAGX) reported its Q3 earnings results on Wednesday, November 17, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Jaguar Health: Q3 Earnings Insights

Mytesi ® prescription volume increased 7.6% in Q3 2021 over Q2 2021 Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million Company expects to complete transition to selling Mytesi through closed specialty pharmacy network by end of 2021 as part of Company's market access strategy Upcoming December 2021 milestones: Presentation of Phase 2 HALT-D study results at San Antonio Breast Cancer Symposium & launch of Canalevia™-CA1 for chemotherapy-induced diarrhea in dogs REMINDER: Jaguar to host investor webcast today (Wednesday, November 17th) at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 17, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated third quarter 2021 financial results.

Jaguar Health Reports 2021 Third Quarter Financial Results

Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Wednesday, 2021-11-17. Here's what investors need to know before the announcement.

Jaguar Health's Earnings Outlook

REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 16, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment of Massimo Mineo, a veteran of Europe's pharmaceutical industry for 20+ years, as Napo EU's general manager.

Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager

Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's investor webcast to review third-quarter 2021 financials and provide business updates will take place at 8:30 a.m. Eastern Time on Wednesday, November 17, 2021 instead of today.

Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time

Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.

Earnings Preview: Jaguar Health

Click here to register for webcast Company plans to file Q3 2021 10-Q on November 15, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday, November 15, 2021 at 8:30 a.m. Eastern Time to review third-quarter 2021 financials and provide business updates.

Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates

SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment by Napo EU S.p.A., the company's Italian subsidiary, of Annabella Amatulli as chief regulatory officer.

Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer

Canalevia™-CA1 is the first and only oral plant-based prescription drug candidate for CID in dogs Jaguar kicks off educational awareness contest in honor of International Jaguar Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / November 2, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it has completed the filing of the New Animal Drug Application (NADA) to request the U.S. Food and Drug Administration's conditional approval to market Canalevia™-CA1 (crofelemer delayed-release tablets), Jaguar's oral plant-based prescription drug candidate for the treatment of chemotherapy-induced diarrhea (CID) in dogs. "All required major and minor technical sections of our application for conditional approval of Canalevia for CID in dogs have been deemed ‘Complete' by the CVM, and filing of the NADA is an administrative activity that results in approval for commercialization 60 days later.

Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch

The combined entity is named Napo EU S.p.A. SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the merger of its Italian subsidiary Napo EU S.p.A.

The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A.

Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2 HALT-D study evaluating crofelemer for prevention and prophylaxis of diarrhea in breast cancer patients as a poster for December 2021 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA / ACCESSWIRE / October 7, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) provided updates today regarding ongoing research and development related to the company's crofelemer drug product candidates, and also announced that Dragon SPAC S.p.A. and Napo EU S.p.A.

Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.

Award celebrates Ms. Conte's 30-year, unrelenting commitment to supporting Indigenous communities in the Amazon and responsibly harvesting and commercializing the first-ever plant-based oral medicine approved under FDA Botanical Guidance SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Pure Earth, an international non-profit organization that is a leader in the global fight to reduce disease-causing pollution, is awarding Jaguar's Founder, President, and Chief Executive Officer Lisa Conte with an Impact Award.

Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award

Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy Virtual event 1:00 PM to 2:10 PM Eastern Registration open now for financial and business community; Click here to register SAN FRANCISCO, CA / ACCESSWIRE / September 27, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Ladenburg Thalmann is hosting an R&D Showcase webinar about cancer therapy-related diarrhea (CTD) on September 29, 2021 from 1:00 p.m. to 2:10 p.m.

Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021

Jaguar planning for launch of Canalevia™ for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA / ACCESSWIRE / September 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it was informed on September 21, 2021 by the FDA's Center for Veterinary Medicine (CVM) that the Target Animal Safety (TAS) technical section of the company's application for conditional approval of Canalevia for chemotherapy-induced diarrhea (CID) under the Minor Use/Minor Species (MUMS) section of The Minor Use and Minor Species Animal Health Act of 2004 has been deemed "Complete". The TAS section - the last of the four major technical sections of Jaguar's application - describes testing undertaken to show that a drug candidate is safe for use under the conditions for which the drug will be prescribed following its approval.

Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs

Click here to register for webcast Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday, September 20, 2021 at 8:30 a.m. Eastern Time.

REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time

The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals Jaguar to host investor webcast Monday, September 20th at 8:30 a.m. Eastern; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / September 15, 2021 / Jaguar Health (NASDAQ:JAGX) today announced that the European Medicines Agency (EMA) has confirmed that the Orphan Drug Designation (ODD) application for crofelemer submitted by Napo EU S.p.A.

Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency

Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A.

News for Jaguar Health Stock (JAGX)